Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rani Therapeutics appointed Nicholas Maestas as its new Chief Financial Officer, granting him an inducement award of 2 million stock options. The options have an exercise price of $0.6973 per share, vesting over four years with a ten-year term.
Key figures
- Exercise price
- 0.6973
- Options granted
- 2000000
- Vesting schedule
- 4 years
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.